Health Care • Biotechnology: Pharmaceutical Preparations
$0.86 ▼ -0.05
(-5.91%)
MKT CAP: $10.0M • VOL: 26.7K
52W L $1 52W H $4
ROARABLE / RQD
D- • 42/100
PIOTROSKI
1 / 9
PHIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.2M | -$7.4M | -$10.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$8.7M | -$7.2M | -$10.8M |
| EBITDA (Normalized) | -$9.2M | -$7.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.0M | -$7.1M | -$10.7M |
| Capital Expenditures (CapEx) | $12.0K | $1.0K | — |
| Free Cash Flow (FCF) | -$8.0M | -$7.1M | -$10.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $21.0M | $5.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $20.1M | $4.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PHIO.